Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Cardiologists Specializing in Lipids (US)

Articles with lock require a subscription to GLG News | Request a free trial
August 6, 2008
Statin therapy for children
Analysis of: 8-Year-Olds on Statins? A New Plan Quickly Bites Back | www.nytimes.com
Author: GLG Expert Contributor
The  potential market for treatment of lipids(cholesterol)continues to grow. Recent recommendations regarding potential for treatment of children as young as 8 are controversial, primarily because of the lack of data to demonstrate efficacy in terms of "hard" endpoints(i.e. mortality/MI)vs. morbidity...
July 28, 2008
Economic Forces Leading to Use of More Generic Medications
Analysis of: Patients Curb Prescription Spending | online.wsj.com
Author: GLG Expert Contributor
Given the economic pressures on patients, they are now more likely to ask for generic medications than they were in the past.  Given that there are generic versions of several classes of medications, physicians such as me are more likely to comply with a patient's request for a generic than in...
May 28, 2008
Tekturna scripts
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com
Author: GLG Expert Contributor
I am a heavy user of ARB's and Tekturna.  This article does not really show anything of significance.  Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
January 18, 2008
Outsourcing of compassionate use of drugs?
Analysis of: No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
Author: Dan Streja, Clinical Professor of Medicine, University of California, Los Angeles
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...
Samuel ButmanJanuary 17, 2008
First Impressions Carry the Day and the Year -Vytorin Loses in ENHANCE
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com
Author: Samuel Butman, Interventional Cardiologist, Verde Valley Heart LLC
The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant.   The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...
November 23, 2007
Risk Versus Benefit
Analysis of: Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
Author: Ramin Ebrahimi, Director of Cardiac Catheterization Lab, Wadsworth VA Medical Center
The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.
November 8, 2007
Another piece of good news for a very good drug
Analysis of: Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
Author: Howard Weintraub, Clinical Director, NYU Medical Center
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...
November 8, 2007
Even more benefit.
Analysis of: Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
Author: Howard Weintraub, Clinical Director, NYU Medical Center
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
October 31, 2007
Undue Pessimism
Analysis of: Phase 2 Prasugrel Studies Suspended Prior to Release of Major Phase 3 Trial | www.medscape.com
Author: GLG Expert Contributor
The devil is in the details! Far from disappointing, the protocol ammendments (dosing) based on pharmacokinetic analysis that have been effected are both prudent and reassuring. Prasugrel dosing is likely being adjusted to reflect its metabolism in various patient populations including the elderly and...
October 26, 2007
Avandia is going down the drain
Analysis of: U.S. veterans dept to limit Glaxo's Avandia: report | www.reuters.com
Author: GLG Expert Contributor
Another large provider votes thumbs-down on Avandia.Actos remains innocent until proven guilty.

Page : 1 2 3 4 Next1 to 10 of 35

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773